CN111629725A - 急性骨髓性白血病的组合治疗 - Google Patents

急性骨髓性白血病的组合治疗 Download PDF

Info

Publication number
CN111629725A
CN111629725A CN201980009504.0A CN201980009504A CN111629725A CN 111629725 A CN111629725 A CN 111629725A CN 201980009504 A CN201980009504 A CN 201980009504A CN 111629725 A CN111629725 A CN 111629725A
Authority
CN
China
Prior art keywords
hydrate
pharmaceutically acceptable
acceptable salt
volasertib
bet inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980009504.0A
Other languages
English (en)
Chinese (zh)
Inventor
U·汤奇-格伦特
A·鲍姆
D·I·鲁道夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN111629725A publication Critical patent/CN111629725A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980009504.0A 2018-01-25 2019-01-24 急性骨髓性白血病的组合治疗 Pending CN111629725A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18153471 2018-01-25
EP18153471.0 2018-01-25
PCT/EP2019/051733 WO2019145410A1 (en) 2018-01-25 2019-01-24 Combination treatment of acute myeloid leukemia

Publications (1)

Publication Number Publication Date
CN111629725A true CN111629725A (zh) 2020-09-04

Family

ID=61198661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980009504.0A Pending CN111629725A (zh) 2018-01-25 2019-01-24 急性骨髓性白血病的组合治疗

Country Status (5)

Country Link
US (1) US20210038602A1 (https=)
EP (1) EP3743067A1 (https=)
JP (1) JP2021511352A (https=)
CN (1) CN111629725A (https=)
WO (1) WO2019145410A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220356525A1 (en) * 2019-10-16 2022-11-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether patients suffering from acute myeloid leukemia will achieve a response to an myc-targeting therapy
WO2022184664A1 (en) 2021-03-02 2022-09-09 Boehringer Ingelheim International Gmbh Anticancer combination therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104870448A (zh) * 2012-11-16 2015-08-26 勃林格殷格翰国际有限公司 三唑并吡嗪
CN104968334A (zh) * 2012-09-28 2015-10-07 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
CN105407923A (zh) * 2013-07-26 2016-03-16 勃林格殷格翰国际有限公司 伏拉塞替与阿扎胞苷组合用于急性骨髓性白血病和骨髓增生异常综合征的治疗ii

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0318145A (pt) 2003-02-26 2006-02-21 Boehringer Ingelheim Pharma dihidropteridinonas, processos para a sua preparação e sua aplicação como medicamento
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
WO2013033270A2 (en) 2011-08-29 2013-03-07 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same
US9422290B2 (en) 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US20150051208A1 (en) * 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428513B2 (en) * 2013-11-07 2016-08-30 Boehringer Ingelheim International Gmbh Triazolopyrazine
US9428515B2 (en) * 2014-05-09 2016-08-30 Boehringer Ingelheim International Gmbh Benzimidazole derivatives
WO2016044694A1 (en) * 2014-09-19 2016-03-24 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104968334A (zh) * 2012-09-28 2015-10-07 翁科埃斯克斯有限公司 包含噻吩并三唑并二氮杂卓化合物的药物制剂
CN104870448A (zh) * 2012-11-16 2015-08-26 勃林格殷格翰国际有限公司 三唑并吡嗪
CN105407923A (zh) * 2013-07-26 2016-03-16 勃林格殷格翰国际有限公司 伏拉塞替与阿扎胞苷组合用于急性骨髓性白血病和骨髓增生异常综合征的治疗ii

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CRISTINA NIETO-JIMÉNEZ等: "Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors" *
DOROTHEA RUDOLPH等: "Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia" *

Also Published As

Publication number Publication date
JP2021511352A (ja) 2021-05-06
EP3743067A1 (en) 2020-12-02
US20210038602A1 (en) 2021-02-11
WO2019145410A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
CN110177791B (zh) 氨基-三唑并吡啶化合物及其在治疗癌症中的用途
EP3269715B1 (en) Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
EP3502103B1 (en) Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor
CN106488910B (zh) Kras g12c的抑制剂
CN106188138B (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
CN102399233B (zh) PI3K和mTOR双重抑制剂类化合物
ES2818620T3 (es) Derivados de azabencimidazol como inhibidores de pi3k beta
CN116457348A (zh) 新型ezh2抑制剂及其用途
WO2017161269A1 (en) Inhibitors of ret receptor tyrosine kinases
AU2008265104A1 (en) Indolin-2-ones and aza-indolin-2-ones
JP2024509268A (ja) 結晶形、それらを含有する組成物、及びそれらの使用方法
CN111788197B (zh) 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途
EP2986609A1 (en) Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CN116194110A (zh) 用于治疗癌症的组合疗法
CA2734077A1 (fr) Derives de 2-alkyl-6-cycloamino-3-(pyridin-4-yl)imidazo[1,2-b]-pyridazine, leur preparation et leur application en therapeutique
CN111629725A (zh) 急性骨髓性白血病的组合治疗
WO2023280317A1 (zh) 苄氨基三并环类化合物及其应用
TW202321256A (zh) ８－氧－３－氮雜雙環［３．２．１］辛烷類化合物或其鹽及其製備方法和用途
ES2761051T3 (es) Derivados de imidazopiridazina como inhibidores de PI3Kbeta
CN120835885A (zh) Cdk2抑制剂
CN106905303A (zh) 一类靶向fak的化合物和其标记物、及它们的制备方法和应用
CN104557913A (zh) 吡啶并嘧啶类化合物，其制备方法和用途
CN104418867B (zh) 作为PI3K/mTOR抑制剂的化合物，其制备方法和用途
WO2020257189A1 (en) Macrocycles for treating disease
AU2015366202A1 (en) Heterocyclyl linked imidazopyridazine derivatives as PI3Kbeta inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200904

WD01 Invention patent application deemed withdrawn after publication